AGEN_OUT_1 [2025-04-17 14:17:35 -0400] 4196 Bytes | 1163 tokens | Cum: 1163 tkns (14.54% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 2:17:34 PM on Thu Apr 17, 2025 -0400, and I'm firing up the spotlight on Agenus (AGEN), moving from 1.6500 to 1.9899. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Agenus (AGEN)
IPO: 2000-02-04 (25 Years Ago)
Market Cap: $45,049,737
Shares Outstanding: 25,310,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Here’s a list of headlines for Agenus:

Apr-10-25 08:52AM - Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
Mar-25-25 04:40PM - Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
Mar-25-25 04:40PM 09:55AM - Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
Mar-19-25 07:30AM - Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
Mar-12-25 03:03AM - Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges
Mar-12-25 03:03AM 01:35AM - Q4 2024 Agenus Inc Earnings Call
Mar-11-25 11:45AM - Agenus (AGEN) Q4 2024 Earnings Call Transcript
Mar-11-25 11:45AM 08:40AM - Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-12T18:00:00Z - MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
B2 - 2025-01-23T19:13:00Z - MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
B3 - 2024-11-12T17:15:14Z - Agenus (AGEN) Q3 2024 Earnings Call Transcript
B4 - 2024-11-02T11:45:00Z - DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Agenus to Contact Us to Have Their Losses Evaluated Today
B5 - 2024-10-31T09:45:00Z - Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AGEN
B6 - 2024-10-30T22:54:00Z - Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Agenus (AGEN).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

AGEN_OUT_3 [2025-04-17 14:17:36 -0400] 867 Bytes | 234 tokens | Cum: 1399 tkns (17.49% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Agenus (AGEN) Q3 2024 Earnings Call Transcript**Date: Unknown DateSource: Unknown SourceURL: https://www.fool.com/earnings/call-transcripts/2024/11/12/agenus-agen-q3-2024-earnings-call-transcript/?source=iedfolrf0000001Agenus, a biotech company, reported its Q3 2024 earnings. The company's lead drug candidate, BOT/BAL, is showing promising results in treating various cancers, including microsatellite stable colorectal cancer. However, Agenus is facing financial challenges and is exploring strategic transactions and asset monetization to support the development of BOT/BAL.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_5 [2025-04-17 14:17:37 -0400] 848 Bytes | 266 tokens | Cum: 1667 tkns (20.84% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T14:10:00Z - Capitalizing On Biotech Market Shifts...
A2 - 2025-04-10T14:02:00Z - Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus...
A3 - 2025-03-25T20:41:45Z - Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025...
A4 - 2025-03-25T20:04:17Z - GSK, UK DEMENTIA Research Institute (UK DRI) and Health Data Research UK (HDR UK)....
A5 - 2025-03-25T15:00:00Z - Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AGEN_OUT_7 [2025-04-17 14:17:38 -0400] 404 Bytes | 107 tokens | Cum: 1776 tkns (22.20% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1):

[INFO] Your document request exceeded 20000 characters. If you need more, please request additional documents separately.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_9 [2025-04-17 14:17:41 -0400] 805 Bytes | 208 tokens | Cum: 1986 tkns (24.82% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S8 - 2025-03-17 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

Overview

Agenus Inc. (including its subsidiaries, collectively referred to as Agenus, the Company, we, us, and our) is a clinical-stage biotechnology company specializing in discover...

S9 - 2025-03-11 8-K Item 2.02 Results of Oper and Fin Cond.

On March 11, 2025, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2024. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AGEN_OUT_11 [2025-04-17 14:17:44 -0400] 1181 Bytes | 274 tokens | Cum: 2262 tkns (28.27% of 8k)
==========================================================================

Showing S8 (chunk 1 of 6): S8:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

Overview

Agenus Inc. (including its subsidiaries, collectively referred to as Agenus, the Company, we, us, and our) is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. Our pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc. ("MiNK")), and vaccine adjuvants (via SaponiQx, Inc. ("SaponiQx")). Our primary focus is immuno-oncology (I-O), and our diverse pipeline is supported by our in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. To succeed in I-O, innovation and speed are paramount. We are a vertically integrated biotechnology company equipped with a suite of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_13 [2025-04-17 14:17:45 -0400] 1181 Bytes | 234 tokens | Cum: 2498 tkns (31.23% of 8k)
==========================================================================

Showing S8 (chunk 2 of 6): technology platforms to advance from novel target identification through manufacturing for clinical trials of antibodies and cell therapies. By understanding each patient's cancer, we aim to substantially expand the population benefiting from current I-O therapies. In addition to a diverse pipeline, we have assembled fully integrated end-to-end capabilities including novel target discovery, antibody generation, cell line development and cGMP manufacturing. Leveraging our science and capabilities, we have established strategic partnerships to advance innovation. We believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined with novel immunomodulatory agents designed to address underlying tumor escape mechanisms.

Our I-O portfolio is driven by several platforms and programs, which we plan to utilize individually and i

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_15 [2025-04-17 14:17:46 -0400] 1181 Bytes | 289 tokens | Cum: 2789 tkns (34.86% of 8k)
==========================================================================

Showing S8 (chunk 3 of 6): n combination:

Multiple antibody discovery platforms, including proprietary display technologies, to identify future antibody candidates.

Antibody candidate programs, including our lead assets, botensilimab ("BOT") (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, also known as AGEN1181) and balstilimab ("BAL") (a programmed death receptor-1 (PD-1) blocking antibody).

Our saponin-based vaccine adjuvant platform, primarily centered around our STIMULON cultured plant cell (cpc) QS-21 adjuvant (STIMULON cpcQS-21).

A pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK.

We regularly evaluate development, commercialization, and partnering strategies for each product candidate based on various factors, includ

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_17 [2025-04-17 14:17:47 -0400] 1181 Bytes | 268 tokens | Cum: 3059 tkns (38.24% of 8k)
==========================================================================

Showing S8 (chunk 4 of 6): ing pre-clinical and clinical trial results, competitive positioning, funding requirements, and available resources. Our lead program, BOT is progressing through multiple clinical programs as a monotherapy and in combination with BAL. In April 2023, BOT in combination with BAL received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with non-microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer without active liver involvement. This designation specifically targets patients who are heavily pretreated and have shown resistance or intolerance to standard chemotherapies, including fluoropyrimidine, oxaliplatin, and irinotecan, as well as those who have received a VEGF inhibitor, an EGFR inhibitor, and/or a BRAF inhibitor, if indicated. Based on the BOT/BAL clinical data generated to

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_19 [2025-04-17 14:17:48 -0400] 1181 Bytes | 290 tokens | Cum: 3351 tkns (41.89% of 8k)
==========================================================================

Showing S8 (chunk 5 of 6): date, we have developed designs for registration-enabling trials in MSS CRC across neoadjuvant, first-line, and late-line mCRC. These trial(s) will launch upon completion of strategic transactions. The options being considered are partnerships, licensing, or joint ventures.

We have entered into collaborations with several companies, including Bristol-Myers Squibb Company (BMS), Betta Pharmaceuticals Co., Ltd. (Betta), UroGen Pharma Ltd. (UroGen), Gilead Sciences, Inc. (Gilead), Incyte Corporation (Incyte), and Merck Sharp Dohme (Merck). These collaborations, along with our internal programs, have resulted in over a dozen antibody pre-clinical or clinical development programs.

Pursuant to our collaboration agreement with Incyte, we had exclusively licensed to Incyte monospecific antibodies targeting GITR, OX40, TIM-3 and LAG-3, as well as an additional undisclosed target. Under the te

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_21 [2025-04-17 14:17:48 -0400] 790 Bytes | 194 tokens | Cum: 3547 tkns (44.34% of 8k)
==========================================================================

Showing S8 (chunk 6 of 6): rms of our agreement, Incyte was responsible for all future development expenses, and we were eligible to receive up to an additional $315.0 million in potential milestone payments plus royalties on any future sales. Incyte has terminated the OX40 program, effective October 2023, and both the GITR program and undisclosed program, effective May 2024. Upon termination, the rights to the OX40, GITR, and undisclosed programs reverted back to us. In July 2024, Incyte announced that it would discontinue f...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_23 [2025-04-17 14:17:54 -0400] 6878 Bytes | 1918 tokens | Cum: 5467 tkns (68.34% of 8k)
==========================================================================

This is our set of metrics for Agenus.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 304,212 | Perf Month: 12.43% | Option/Short: Yes / Yes | Sales Y/Y TTM: -33.81% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 434.14K | Perf Quarter: -38.25% | Short Float: 15.29% | ROE: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 0.98 | Index: RUT | Short Ratio: 8.68 | ROI: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 53.18 | Market Cap: 49.23M | Short Interest: 3.77M | Sales Surprise: -11.35% |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.19 | Shs Outstand: 25.31M | Beta: 1.50 | EPS Surprise: 19.75% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 16.48% | Shs Float: 24.65M | Sales Q/Q: -67.98% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -15.54% | Inst Own: 32.15% | Sales past 5Y: 30.58% | Earnings: Mar 11 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -56.49% | Insider Own: 2.60% | Employees: 316 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 20.06% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by Agenus officers or majority shareholders (if available).

Inside Trans: AGENUS INC (AGEN) by Buell Jennifer (Unknown Title) on 2025-04-04
- Common Stock: 1159 shares at $1.56 (D)

Inside Trans: AGENUS INC (AGEN) by ARMEN GARO H (See Remarks) on 2025-04-04
- Common Stock: 10288 shares at $1.56 (D)

Inside Trans: AGENUS INC (AGEN) by HARRISON THOMAS L (Unknown Title) on 2025-04-01
- Common Stock: 8898 shares at $2.88 (D)

Inside Trans: AGENUS INC (AGEN) by Wright Timothy (Unknown Title) on 2025-04-01
- Deferred Stock Units: 3255.585 shares at $N/A (D)

Inside Trans: AGENUS INC (AGEN) by Buell Jennifer (Unknown Title) on 2025-03-21
- Common Stock: 1123 shares at $1.61 (D)

Inside Trans: AGENUS INC (AGEN) by ARMEN GARO H (See Remarks) on 2025-03-21
- Common Stock: 9243 shares at $1.61 (D)

Inside Trans: AGENUS INC (AGEN) by Buell Jennifer (Unknown Title) on 2025-03-07
- Common Stock: 409 shares at $2.35 (D)

Inside Trans: AGENUS INC (AGEN) by ARMEN GARO H (See Remarks) on 2025-03-07
- Common Stock: 6332 shares at $2.35 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 103463000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -232271000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.9899
Average Volume: 430424.78
30-Day High: 1.9899
30-Day Low: 1.505

[Detailed Financials: TTM 2024]
- Total Assets: $226,271,000.0
- Total Liabilities: $532,695,000.0
- Total Equity: $-306,424,000.0
- Current Assets: $45,574,000.0
- Current Liabilities: $221,401,000.0

[Income Statement: TTM 2024]
- Revenue: $103,463,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.59

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-35,448,000.0

[Detailed Financials: FY 2024]
- Total Assets: $226,271,000.0
- Total Liabilities: $532,695,000.0
- Total Equity: $-306,424,000.0
- Current Assets: $45,574,000.0
- Current Liabilities: $221,401,000.0

[Income Statement: FY 2024]
- Revenue: $103,463,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.59

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-35,448,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Agenus (AGEN).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Agenus.

2) MARKET_SCORE[]
This conversation was initiated because AGEN is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for AGEN.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, AGEN could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect AGEN to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Agenus.

11) ETHICAL_RATING[]
Rate Agenus’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Agenus.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

AGEN_IN_25 [2025-04-17 14:17:54 -0400] 126 Bytes | 29 tokens | Cum: 5675 tkns (70.94% of 8k)
==========================================================================

====================================
[2025-04-17 14:17:54] # Analysis Completed
Elapsed Time: 20.26 seconds